65 Years Caring for Health

Hemofarm, a pharmaceutical leader in the country and region-wide, has marked 65 years of successful operation and continuous development. For six and a half decades, Hemofarm has been dedicated to fulfilling its core mission of caring for people's health by producing high-quality, effective, and affordable pharmaceutical products. In 2024 alone, Hemofarm produced 332 million packages, amounting to approximately 7 billion units of medicines and dietary supplements.

‘The Hemofarm team, comprising over 4,300 skilled and motivated employees across all our factories and business centers, stands behind our success. For many years, we have been recognized as the best employer in Serbia and the region, which is another testament to our commitment to people,’ said Ronald Seeliger, Hemofarm’s CEO, emphasizing that in recent years the company has recorded important milestones in the market:

‘Following the trends in the industry, last year we launched an innovative line of supplements under the umbrella brand „One Two Three“ in Serbia, and EUNOVA, a line of premium supplements, in Bosnia and Herzegovina. This year, we continue with strategic acquisitions aimed at further strengthening our brands in the region, with a strong focus also on the biosimilars market. Our commitment to sustainable development goals is rounded off by organizing the first ESG festival in Serbia, and the socially responsible campaign Let’s Write the Story from the Beginning in B&H and Serbia.‘

Hemofarm demonstrates its commitment to sustainable, responsible and inclusive business also through the fact that women make up 56% of the total headcount. Additionally, in the previous period, the supply of electricity from renewable sources has increased by 15%. Thirteen sustainability reports have been published to date, and the 14th is on the way.

‘Our sustainability strategy is based on the tangible results and systemic changes. I believe that only through responsible business practices can we truly contribute to a healthier society and a better future’, concluded Seeliger.

Founded on June 1st, 1960, in Vršac, Hemofarm currently holds 9.7% of the market share in Serbia, while in the segment of Over-the-Counter (OTC) and Consumer Healthcare (CHC) products, it occupies a leading position with nearly 10% share. The rich portfolio comprises 411 products in various pharmaceutical forms and doses. Since 2006, Hemofarm has been operating within the German STADA Group, one of the global leaders in the field of generics and OTC medicines. To date, more than 475 million euros have been invested in the company's development, strengthening all business segments - from modern technologies and expanding production capacities to socially responsible initiatives.